Product Portfolio And Clinical DifferentiationPreservé and the minimally invasive surgery portfolio offer clinical advantages and appeal to patients who previously avoided implants, creating potential to expand the addressable market and lift average selling prices.
Profitability And Cash Flow TrajectoryImproving gross margins and management's expectation of a positive cash-flow quarter in 2026 underpin a credible path to sustained adjusted profitability and annual free-cash-flow positivity.
U.S. Commercial MomentumStrong U.S. launch of Motiva, supported by surgeon adoption and direct-to-patient marketing, is driving market share gains and U.S. revenue that is tracking ahead of prior company guidance.